{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:30:59Z","timestamp":1760149859403,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Tasmania Pharmacy Appeal Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The use of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) and low stroke risk might cause more harm than benefit. Little attention has been given to address its prevalence and associated consequences. This study aimed to investigate the prescription rate of OACs, identify associated factors, and describe incident bleeding events in low-risk patients. Methods: We included patients with a new diagnosis of AF between 1 January 2011 and 31 December 2018 having a low risk of stroke (CHA2DS2-VASc score of 0 for males and 1 for females) from Australian general practice data (MedicineInsight). Patients were classified as OAC users if there was a recorded prescription of an OAC within 60 days of AF diagnosis, and factors associated with the prescription of an OAC were assessed using logistic regression. Recorded incident bleeding events were identified within 6 months after AF diagnosis or after OAC initiation for OAC non-users and users, respectively. The risk of bleeding was compared between the two groups by adjusting their baseline differences using propensity score matching. Results: The study included 2810 low-risk patients (62.3% male) with a mean age of 49.3 \u00b1 10.8 years. Of the total, 705 (25.1%) patients had a record of OAC prescription within 60 days of diagnosis of AF. Older age (odds ratio [OR] 1.03; 95% confidence interval [CI] 1.03\u20131.04) and diagnosis periods (2015\u20132016 [OR 1.46; 95% CI 1.10\u20131.94] and 2017\u20132018 [OR 1.65; 95% CI 1.17\u20132.23] vs. 2011\u20132012) were associated with higher odds of OAC initiation. Female sex (OR 0.71; 95% CI 0.59\u20130.85), higher bleeding risk (ORBIT score; OR 0.80; 95% CI 0.68\u20130.94), and higher socioeconomic index for areas (SEIFA) quintiles (SEIFA quintiles; 2 [OR 0.65; 95% CI 0.48\u20130.88], 3 [OR 0.74; 95% CI 0.56\u20130.98], 4 [OR 0.70; 95% CI 0.52\u20130.94], 5 [OR 0.69; 95% CI 0.52\u20130.91] compared with quintile 1) were associated with lower odds of OAC prescription. A total of 52 (in 1.8% of patients) incident bleeds were identified, with 18 (2.6%) among OAC users. The rate of bleeding was not significantly different between users and non-users after matching. However, within OAC users, commencement of OAC was associated with an increased risk of bleeding compared to the period before OAC initiation (p = 0.006). Conclusions: One in four patients at low risk of stroke received an OAC within 60 days of AF diagnosis. Older age and the period following the widespread availability of direct-acting OACs were associated with an increased likelihood of OAC prescription. Positively, using OACs was not associated with an increased rate of bleeding compared to non-users.<\/jats:p>","DOI":"10.3390\/jcm12196182","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T03:45:23Z","timestamp":1695699923000},"page":"6182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral Anticoagulant Use in Patients with Atrial Fibrillation at Low Risk of Stroke and Associated Bleeding Complications"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7254-4435","authenticated-orcid":false,"given":"Adane Teshome","family":"Kefale","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-6949","authenticated-orcid":false,"given":"Woldesellassie M.","family":"Bezabhe","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3882","authenticated-orcid":false,"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort: The Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation","volume":"130","author":"Wann","year":"2014","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger, D., Amerena, J., Attia, J., Bajorek, B., Chan, K.H., Connell, C., Freedman, B., Ferguson, C., and Hall, T. (2018). National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung. Circ., 27, 1209\u20131266.","DOI":"10.1016\/j.hlc.2018.06.1043"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"586370","DOI":"10.3389\/fphar.2021.586370","article-title":"Ten-year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients with Atrial Fibrillation","volume":"12","author":"Bezabhe","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_9","first-page":"887","article-title":"Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: A systematic review and meta-analysis","volume":"24","author":"Grymonprez","year":"2022","journal-title":"EP Eur."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/cpt.1024","article-title":"Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: A Contemporary Review","volume":"104","author":"Hsu","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1161\/STROKEAHA.118.021990","article-title":"Improved Stroke Prevention in Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants","volume":"49","author":"Forslund","year":"2018","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42444-021-00053-9","article-title":"Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants","volume":"23","author":"Park","year":"2022","journal-title":"Int. J. Arrhythm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/eurheartj\/ehac111","article-title":"Oral anticoagulants in patients with atrial fibrillation at low stroke risk: A multicentre observational study","volume":"43","author":"Komen","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamainternmed.2015.0920","article-title":"Oral Anticoagulant Prescription in Patients with Atrial Fibrillation and a Low Risk of Thromboembolism: Insights from the NCDR PINNACLE Registry","volume":"175","author":"Hsu","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_15","first-page":"1400","article-title":"Underprescribing vs underfilling to oral anticoagulation: An analysis of linked medical record and claims data for a nationwide sample of patients with atrial fibrillation","volume":"28","author":"Guo","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral Anticoagulant Therapy Prescription in Patients with Atrial Fibrillation across the Spectrum of Stroke Risk: Insights from the NCDR PINNACLE Registry","volume":"1","author":"Hsu","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/eurheartj\/ehz304","article-title":"Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation","volume":"40","author":"Friberg","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e023098","DOI":"10.1161\/JAHA.121.023098","article-title":"Oral Anticoagulant Treatment and the Risk of Dementia in Patients with Atrial Fibrillation: A Population-Based Cohort Study","volume":"11","author":"Bezabhe","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/joa3.12781","article-title":"Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial)","volume":"38","author":"Bunch","year":"2022","journal-title":"J. Arrhythm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e12956","DOI":"10.1002\/emp2.12956","article-title":"Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: A real-world analysis of Medicare beneficiaries","volume":"4","author":"Williams","year":"2023","journal-title":"J. Am. Coll. Emerg. Physicians Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2023.03.010","article-title":"Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016\u20132020","volume":"225","author":"Geller","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13457","DOI":"10.1111\/eci.13457","article-title":"Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation","volume":"51","author":"Bezabhe","year":"2020","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_23","unstructured":"(2021). MedicineInsight Data Book Version 4.0, NPS MedicineWise."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Havard, A., Manski-Nankervis, J.-A., Thistlethwaite, J., Daniels, B., Myton, R., Tu, K., and Chidwick, K. (2021). Validity of algorithms for identifying five chronic conditions in MedicineInsight, an Australian national general practice database. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-06593-z"},{"key":"ref_25","unstructured":"Busingye, D., Myton, R., Mina, R., Thistlethwaite, J., Belcher, J., and Chidwick, K. (2020). MedicineInsight Report: Validation of the MedicineInsight Database: Completeness, Generalisability and Plausibility, NPS MedicineWise."},{"key":"ref_26","first-page":"1741","article-title":"Data Resource Profile: MedicineInsight, an Australian national primary health care database","volume":"48","author":"Busingye","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"ref_27","unstructured":"The Royal Australian College of General Practitioners (2020). Standards for General Practices, RACGP."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"CHEST"},{"key":"ref_29","first-page":"3258","article-title":"The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"Simon","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_30","unstructured":"Australian Bureau of Statistics (2019). Australian Statistical Geography Standard, Australian Bureau of Statistics."},{"key":"ref_31","unstructured":"Australian Bureau of Statistics (2016). Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australian Bureau of Statistics."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e239973","DOI":"10.1001\/jamanetworkopen.2023.9973","article-title":"Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/heartjnl-2021-319338","article-title":"Trends in the pharmacological management of atrial fibrillation in UK general practice 2008\u20132018","volume":"108","author":"Phillips","year":"2022","journal-title":"Heart"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40256-020-00457-3","article-title":"Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence","volume":"21","author":"Gebreyohannes","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1060028020904969","article-title":"The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex","volume":"54","author":"Pilcher","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_37","first-page":"290","article-title":"Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature","volume":"115","author":"Daly","year":"2023","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_38","first-page":"771","article-title":"Oral anticoagulant underutilization among elderly patients with atrial fibrillation: Insights from the United States Medicare database","volume":"66","author":"Munir","year":"2023","journal-title":"J. Interv. Card Electrophysiol."},{"key":"ref_39","first-page":"103","article-title":"Race\/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data","volume":"112","author":"Essien","year":"2020","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a Warfarin-Treated Population with Atrial Fibrillation","volume":"1","author":"Bjorck","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_41","unstructured":"Amaraneni, A., Chippa, V., and Rettew, A. (2023, August 18). Anticoagulation Safety, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519025\/."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:57:40Z","timestamp":1760129860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":41,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12196182"],"URL":"https:\/\/doi.org\/10.3390\/jcm12196182","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,9,25]]}}}